BCL2L1 and small cell lung carcinoma: Preclinical studies have shown that the BCL-2/BCL-XL inhibitor navitoclax is able to decrease the proliferation of SCLC cells; however, this promising preclinical activity failed to translate into a successful clinical activity in SCLC [111].